Changes of placental syndecan-1 expression in preeclampsia and HELLP syndrome

Szilvia Szabo, Yi Xu, Roberto Romero, T. Füle, Katalin Karaszi, Gaurav Bhatti, Tibor Varkonyi, Ildiko Varkonyi, T. Krenács, Zhong Dong, Adi L. Tarca, Tinnakorn Chaiworapongsa, Sonia S. Hassan, Z. Papp, I. Kovalszky, Nandor Gabor Than

Research output: Article

23 Citations (Scopus)

Abstract

Preeclampsia is characterized by maternal systemic anti-angiogenic and pro-inflammatory states. Syndecan-1 is a cell surface proteoglycan expressed by the syncytiotrophoblast, which plays an important role in angiogenesis and resolution of inflammation. Our aim was to examine placental syndecan-1 expression in preeclampsia with or without hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome. Placentas were obtained from women in the following groups: (1) late-onset preeclampsia (n = 8); (2) early-onset preeclampsia without (n = 7) and (3) with HELLP syndrome (n = 8); (4) preterm controls (n = 5); and (5) term controls (n = 9). Tissue microarrays (TMAs) were constructed from paraffin-embedded placentas. TMA slides were immunostained for syndecan-1 and evaluated using microscopy, virtual microscopy, and semi-automated image analysis. Maternal sera from patients with preeclampsia (n = 49) and controls (n = 32) were immunoassayed for syndecan-1. BeWo cells were treated with Forskolin or Latrunculin B or kept in ischemic conditions. SDC1 expression and syndecan-1 production were investigated with qRT-PCR, confocal microscopy, and immunoassays. Syndecan-1 was localized to the syncytiotrophoblast apical membrane in normal placentas. Syndecan-1 immunoscores were higher in late-onset preeclampsia (p = 0.0001) and early-onset preeclampsia with or without HELLP syndrome (p = 0.02 for both) than in controls. Maternal serum syndecan-1 concentration was lower in preeclampsia (median, 673 ng/ml; interquartile range, 459-1,161 ng/ml) than in controls (1,158 ng/ml; 622-1,480 ng/ml). SDC1 expression and syndecan-1 immunostainings in BeWo cells and syndecan-1 concentrations in supernatants increased during cell differentiation. Disruption of the actin cytoskeleton with Latrunculin B decreased syndecan-1 release, while ischemic conditions increased it. Syncytiotrophoblastic syndecan-1 expression depends on the differentiation of villous trophoblasts, and trophoblastic syndecan-1 release is decreased in preeclampsia and HELLP syndrome. This phenomenon may be related to the disturbed syncytiotrophoblastic cortical actin cytoskeleton and associated with maternal anti-angiogenic and pro-inflammatory states in these syndromes.

Original languageEnglish
Pages (from-to)445-458
Number of pages14
JournalVirchows Archiv
Volume463
Issue number3
DOIs
Publication statusPublished - szept. 2013

Fingerprint

Syndecan-1
Hemolysis
Pre-Eclampsia
Platelet Count
Liver
Enzymes
Trophoblasts
Mothers
Placenta
Actin Cytoskeleton
Microscopy
Colforsin
Proteoglycans
Serum
Immunoassay
Confocal Microscopy

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Cell Biology
  • Molecular Biology

Cite this

Szabo, S., Xu, Y., Romero, R., Füle, T., Karaszi, K., Bhatti, G., ... Than, N. G. (2013). Changes of placental syndecan-1 expression in preeclampsia and HELLP syndrome. Virchows Archiv, 463(3), 445-458. https://doi.org/10.1007/s00428-013-1426-0

Changes of placental syndecan-1 expression in preeclampsia and HELLP syndrome. / Szabo, Szilvia; Xu, Yi; Romero, Roberto; Füle, T.; Karaszi, Katalin; Bhatti, Gaurav; Varkonyi, Tibor; Varkonyi, Ildiko; Krenács, T.; Dong, Zhong; Tarca, Adi L.; Chaiworapongsa, Tinnakorn; Hassan, Sonia S.; Papp, Z.; Kovalszky, I.; Than, Nandor Gabor.

In: Virchows Archiv, Vol. 463, No. 3, 09.2013, p. 445-458.

Research output: Article

Szabo, S, Xu, Y, Romero, R, Füle, T, Karaszi, K, Bhatti, G, Varkonyi, T, Varkonyi, I, Krenács, T, Dong, Z, Tarca, AL, Chaiworapongsa, T, Hassan, SS, Papp, Z, Kovalszky, I & Than, NG 2013, 'Changes of placental syndecan-1 expression in preeclampsia and HELLP syndrome', Virchows Archiv, vol. 463, no. 3, pp. 445-458. https://doi.org/10.1007/s00428-013-1426-0
Szabo, Szilvia ; Xu, Yi ; Romero, Roberto ; Füle, T. ; Karaszi, Katalin ; Bhatti, Gaurav ; Varkonyi, Tibor ; Varkonyi, Ildiko ; Krenács, T. ; Dong, Zhong ; Tarca, Adi L. ; Chaiworapongsa, Tinnakorn ; Hassan, Sonia S. ; Papp, Z. ; Kovalszky, I. ; Than, Nandor Gabor. / Changes of placental syndecan-1 expression in preeclampsia and HELLP syndrome. In: Virchows Archiv. 2013 ; Vol. 463, No. 3. pp. 445-458.
@article{3b5fd4929cd84ad3ba41f3a9a54ba487,
title = "Changes of placental syndecan-1 expression in preeclampsia and HELLP syndrome",
abstract = "Preeclampsia is characterized by maternal systemic anti-angiogenic and pro-inflammatory states. Syndecan-1 is a cell surface proteoglycan expressed by the syncytiotrophoblast, which plays an important role in angiogenesis and resolution of inflammation. Our aim was to examine placental syndecan-1 expression in preeclampsia with or without hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome. Placentas were obtained from women in the following groups: (1) late-onset preeclampsia (n = 8); (2) early-onset preeclampsia without (n = 7) and (3) with HELLP syndrome (n = 8); (4) preterm controls (n = 5); and (5) term controls (n = 9). Tissue microarrays (TMAs) were constructed from paraffin-embedded placentas. TMA slides were immunostained for syndecan-1 and evaluated using microscopy, virtual microscopy, and semi-automated image analysis. Maternal sera from patients with preeclampsia (n = 49) and controls (n = 32) were immunoassayed for syndecan-1. BeWo cells were treated with Forskolin or Latrunculin B or kept in ischemic conditions. SDC1 expression and syndecan-1 production were investigated with qRT-PCR, confocal microscopy, and immunoassays. Syndecan-1 was localized to the syncytiotrophoblast apical membrane in normal placentas. Syndecan-1 immunoscores were higher in late-onset preeclampsia (p = 0.0001) and early-onset preeclampsia with or without HELLP syndrome (p = 0.02 for both) than in controls. Maternal serum syndecan-1 concentration was lower in preeclampsia (median, 673 ng/ml; interquartile range, 459-1,161 ng/ml) than in controls (1,158 ng/ml; 622-1,480 ng/ml). SDC1 expression and syndecan-1 immunostainings in BeWo cells and syndecan-1 concentrations in supernatants increased during cell differentiation. Disruption of the actin cytoskeleton with Latrunculin B decreased syndecan-1 release, while ischemic conditions increased it. Syncytiotrophoblastic syndecan-1 expression depends on the differentiation of villous trophoblasts, and trophoblastic syndecan-1 release is decreased in preeclampsia and HELLP syndrome. This phenomenon may be related to the disturbed syncytiotrophoblastic cortical actin cytoskeleton and associated with maternal anti-angiogenic and pro-inflammatory states in these syndromes.",
keywords = "Cell signaling, Pregnancy, Proteoglycan, Syncytiotrophoblast, Systemic inflammation, Virtual microscopy",
author = "Szilvia Szabo and Yi Xu and Roberto Romero and T. F{\"u}le and Katalin Karaszi and Gaurav Bhatti and Tibor Varkonyi and Ildiko Varkonyi and T. Kren{\'a}cs and Zhong Dong and Tarca, {Adi L.} and Tinnakorn Chaiworapongsa and Hassan, {Sonia S.} and Z. Papp and I. Kovalszky and Than, {Nandor Gabor}",
year = "2013",
month = "9",
doi = "10.1007/s00428-013-1426-0",
language = "English",
volume = "463",
pages = "445--458",
journal = "Virchows Archiv - A Pathological Anatomy and Histopathology",
issn = "0945-6317",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Changes of placental syndecan-1 expression in preeclampsia and HELLP syndrome

AU - Szabo, Szilvia

AU - Xu, Yi

AU - Romero, Roberto

AU - Füle, T.

AU - Karaszi, Katalin

AU - Bhatti, Gaurav

AU - Varkonyi, Tibor

AU - Varkonyi, Ildiko

AU - Krenács, T.

AU - Dong, Zhong

AU - Tarca, Adi L.

AU - Chaiworapongsa, Tinnakorn

AU - Hassan, Sonia S.

AU - Papp, Z.

AU - Kovalszky, I.

AU - Than, Nandor Gabor

PY - 2013/9

Y1 - 2013/9

N2 - Preeclampsia is characterized by maternal systemic anti-angiogenic and pro-inflammatory states. Syndecan-1 is a cell surface proteoglycan expressed by the syncytiotrophoblast, which plays an important role in angiogenesis and resolution of inflammation. Our aim was to examine placental syndecan-1 expression in preeclampsia with or without hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome. Placentas were obtained from women in the following groups: (1) late-onset preeclampsia (n = 8); (2) early-onset preeclampsia without (n = 7) and (3) with HELLP syndrome (n = 8); (4) preterm controls (n = 5); and (5) term controls (n = 9). Tissue microarrays (TMAs) were constructed from paraffin-embedded placentas. TMA slides were immunostained for syndecan-1 and evaluated using microscopy, virtual microscopy, and semi-automated image analysis. Maternal sera from patients with preeclampsia (n = 49) and controls (n = 32) were immunoassayed for syndecan-1. BeWo cells were treated with Forskolin or Latrunculin B or kept in ischemic conditions. SDC1 expression and syndecan-1 production were investigated with qRT-PCR, confocal microscopy, and immunoassays. Syndecan-1 was localized to the syncytiotrophoblast apical membrane in normal placentas. Syndecan-1 immunoscores were higher in late-onset preeclampsia (p = 0.0001) and early-onset preeclampsia with or without HELLP syndrome (p = 0.02 for both) than in controls. Maternal serum syndecan-1 concentration was lower in preeclampsia (median, 673 ng/ml; interquartile range, 459-1,161 ng/ml) than in controls (1,158 ng/ml; 622-1,480 ng/ml). SDC1 expression and syndecan-1 immunostainings in BeWo cells and syndecan-1 concentrations in supernatants increased during cell differentiation. Disruption of the actin cytoskeleton with Latrunculin B decreased syndecan-1 release, while ischemic conditions increased it. Syncytiotrophoblastic syndecan-1 expression depends on the differentiation of villous trophoblasts, and trophoblastic syndecan-1 release is decreased in preeclampsia and HELLP syndrome. This phenomenon may be related to the disturbed syncytiotrophoblastic cortical actin cytoskeleton and associated with maternal anti-angiogenic and pro-inflammatory states in these syndromes.

AB - Preeclampsia is characterized by maternal systemic anti-angiogenic and pro-inflammatory states. Syndecan-1 is a cell surface proteoglycan expressed by the syncytiotrophoblast, which plays an important role in angiogenesis and resolution of inflammation. Our aim was to examine placental syndecan-1 expression in preeclampsia with or without hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome. Placentas were obtained from women in the following groups: (1) late-onset preeclampsia (n = 8); (2) early-onset preeclampsia without (n = 7) and (3) with HELLP syndrome (n = 8); (4) preterm controls (n = 5); and (5) term controls (n = 9). Tissue microarrays (TMAs) were constructed from paraffin-embedded placentas. TMA slides were immunostained for syndecan-1 and evaluated using microscopy, virtual microscopy, and semi-automated image analysis. Maternal sera from patients with preeclampsia (n = 49) and controls (n = 32) were immunoassayed for syndecan-1. BeWo cells were treated with Forskolin or Latrunculin B or kept in ischemic conditions. SDC1 expression and syndecan-1 production were investigated with qRT-PCR, confocal microscopy, and immunoassays. Syndecan-1 was localized to the syncytiotrophoblast apical membrane in normal placentas. Syndecan-1 immunoscores were higher in late-onset preeclampsia (p = 0.0001) and early-onset preeclampsia with or without HELLP syndrome (p = 0.02 for both) than in controls. Maternal serum syndecan-1 concentration was lower in preeclampsia (median, 673 ng/ml; interquartile range, 459-1,161 ng/ml) than in controls (1,158 ng/ml; 622-1,480 ng/ml). SDC1 expression and syndecan-1 immunostainings in BeWo cells and syndecan-1 concentrations in supernatants increased during cell differentiation. Disruption of the actin cytoskeleton with Latrunculin B decreased syndecan-1 release, while ischemic conditions increased it. Syncytiotrophoblastic syndecan-1 expression depends on the differentiation of villous trophoblasts, and trophoblastic syndecan-1 release is decreased in preeclampsia and HELLP syndrome. This phenomenon may be related to the disturbed syncytiotrophoblastic cortical actin cytoskeleton and associated with maternal anti-angiogenic and pro-inflammatory states in these syndromes.

KW - Cell signaling

KW - Pregnancy

KW - Proteoglycan

KW - Syncytiotrophoblast

KW - Systemic inflammation

KW - Virtual microscopy

UR - http://www.scopus.com/inward/record.url?scp=84884146687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884146687&partnerID=8YFLogxK

U2 - 10.1007/s00428-013-1426-0

DO - 10.1007/s00428-013-1426-0

M3 - Article

C2 - 23807541

AN - SCOPUS:84884146687

VL - 463

SP - 445

EP - 458

JO - Virchows Archiv - A Pathological Anatomy and Histopathology

JF - Virchows Archiv - A Pathological Anatomy and Histopathology

SN - 0945-6317

IS - 3

ER -